| Unique ID issued by UMIN | UMIN000061829 |
|---|---|
| Receipt number | R000070744 |
| Scientific Title | A verification study to evaluate the safety of excessive consumption of the test food: an open-label study |
| Date of disclosure of the study information | 2026/06/08 |
| Last modified on | 2026/06/08 16:57:36 |
A verification study to evaluate the safety of excessive consumption of the test food
A verification study to evaluate the safety of excessive consumption of the test food
A verification study to evaluate the safety of excessive consumption of the test food: an open-label study
A verification study to evaluate the safety of excessive consumption of the test food
| Japan |
Healthy Japanese
| Not applicable | Adult |
Others
NO
To verify the safety of excessive consumption of the test food in healthy Japanese.
Safety
Confirmatory
Pragmatic
Not applicable
1. Individuals who experienced adverse events
1. Individuals whose values of urinalysis and peripheral blood test are outside the reference range after intervention despite within the reference range at screening
2. Physical measurements, urinalysis, and peripheral blood test
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Educational,Counseling,Training
| Food |
Duration: 4 weeks
Test product: Microalgae supplements (Moneru)
Administration:
Consume twenty capsules daily (morning, noon, and night) with water.
*If a take is missed, it should be consumed as soon as remembered. The daily take should be consumed within the same day and should not be carried over to the following day.
| 18 | years-old | <= |
| Not applicable |
Male and Female
1. Japanese
2. Men or women
3. Adults
4. Healthy individuals
1. Individuals who are receiving treatment for or have a history of malignant tumors, heart failure, or myocardial infarction
2. Individuals who have an implanted pacemaker or implantable cardioverter defibrillator
3. Individuals who are currently undergoing treatment for any of the following chronic diseases:
cardiac arrhythmia, liver disorder, chronic kidney disease, cerebrovascular disorder, rheumatic disease, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases
4. Individuals who consume Foods for Specified Health Uses or Foods with Functional Claims
5. Individuals who take medicines, herbal medicines, and supplements (particularly vitamin K antagonists such as warfarin).
6. Individuals who are allergic to medications or foods related to the test food (particularly seaweed)
7. Individuals who are pregnant, lactating, or planning pregnancy during this study
8. Individuals who are deemed unsuitable for participation in this study by the principal investigator
15
| 1st name | Tsuyoshi |
| Middle name | |
| Last name | Takara |
Medical Corporation Seishinkai, Takara Clinic
Director
141-0022
9F Taisei Bldg., 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan
03-5793-3623
t-takara@takara-clinic.com
| 1st name | Naoko |
| Middle name | |
| Last name | Suzuki |
ORTHOMEDICO Inc.
R&D Department
112-0002
2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan
03-3818-0610
nao@orthomedico.jp
Algal Bio Co., Ltd.
Algal Bio Co., Ltd.
Profit organization
The ethical committee of the Takara Clinic, Medical Corporation Seishinkai
9F Taisei Bldg., 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan
03-5793-3623
IRB@takara-clinic.com
NO
医療法人社団盛心会 タカラクリニック (東京都)
Medical Corporation Seishinkai, Takara Clinic (Tokyo, Japan)
南町医院 (東京都)
Nerima Medical Association, Minami-machi Clinic (Tokyo, Japan)
| 2026 | Year | 06 | Month | 08 | Day |
Unpublished
Open public recruiting
| 2026 | Year | 05 | Month | 27 | Day |
| 2026 | Year | 05 | Month | 27 | Day |
| 2026 | Year | 06 | Month | 08 | Day |
| 2026 | Year | 09 | Month | 04 | Day |
| 2026 | Year | 06 | Month | 08 | Day |
| 2026 | Year | 06 | Month | 08 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000070744